Allergan Aesthetics has introduced AA Signature: SKIN360 in the US, a structured multimodal consultation protocol combining an injectable hydrator, a topical collagen-supporting formulation, and botulinum toxin for patients seeking smoother, more hydrated skin. The company cites internal figures on patient interest, retention, and treatment conversion tied to comprehensive assessment, while noting that the safety and efficacy of the featured products used in combination have not been studied. The launch reflects a broader shift in aesthetic medicine from single-product intervention toward protocolized, whole-face assessment.
Key Points
- First protocol in a planned series of multimodal aesthetic consultations
- Combines injectable hydrator, topical collagen formulation, and botulinum toxin
- Combined-use safety and efficacy of featured products not studied
Longevity Analysis
Skin functions as a barrier, a thermoregulatory surface, and a visible marker of collagen turnover and hydration status, which makes it a legitimate target for structured intervention rather than isolated cosmetic correction. The move toward comprehensive assessment protocols mirrors a principle that holds across health optimization: reading the full picture before layering tools produces better outcomes than sequential product application. The absence of combined-use data is the operative limitation here, and it places the burden on practitioners to sequence interventions deliberately and track response over time rather than assume additive benefit.
Original published by LT Wire, by LT Staff.